A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
The shock and pain of having a close sibling suddenly and violently cut down by a heartless gunman affects different people in many different ways, and in “The Influence of Love and Forgiveness”Hamilton presents his own story so that readers might learn from his example.
His experience taught him about the mind and body connection, and how the mind can heal as well as harm. Hamilton wants to share his experience with those who want to listen.
“Though it is a short story this book is full of information regarding alternative, practical ways of dealing with health challenges,” Hamilton writes. “It explores real emotions of hate and anger and suggests the not so easy ways of dealing with these emotions.”
NEW YORK, July 19 (UPI) -- Ann Romney described the despair she felt after being diagnosed with multiple sclerosis as a "dark hole" in an interview with ABC Thursday.
Romney, wife of presumptive Republican presidential nominee Mitt Romney, gave an emotional and deeply personal interview with ABC's Robin Roberts, aired on Good Morning America.
Romney, 63, described her "darkest hour" to Roberts, telling her she had "ripped up all the pictures" taken of her around the time she was diagnosed.
"Now I can relate to someone who's going through a really hard time," she said. "I can say I know how you feel like. I know how hard it is."
"It humbled me," she said of the illness, now in remission, adding that her husband would not have sought the nomination if she remained ill.
She also used the interview to take shots at President Obama, whose campaign recently accused her husband of a possible felony for allegedly lying about his resignation from the post of CEO of Bain Capital.
"I believe it was beneath the dignity of the office of the president to do something as egregious as that," she said. "To attack someone on that level is, I believe, beneath his dignity."
MSology counters the clutter of opinion and misinformation about MS.
Montreal, QC (PRWEB) July 19, 2012
There is a quiet revolution in the treatment of multiple sclerosis (MS) with a decade-long explosion of research, a wealth of new medications in development, and growing dissatisfaction among patients and their families with how MS is being treated.
Six MS medications are currently approved and another half-dozen will become available over the next few years – creating difficult treatment choices for people living with MS and their families.
“There’s a lot of information on the Internet about MS,” says Steven Manners, Editor of MSology, a new online information service for people affected by MS. “Unfortunately, much of it is out of date, misinformed, or posted by people who want to sell you something. People need the straight facts so they can make informed decisions about their lives.”
MSology (http://www.msology.ca) is a free information service offering the latest research news on MS, tips on living with the disease, and practical advice to help in making decisions. There will be special reports on “hot topics”, such as the benefits of green tea, a discussion of CCSVI (chronic cerebrospinal venous insufficiency), and what is known about vitamin D and MS. Readers will also be able to have their say in the My Voice sections of the website.
As a complex and unpredictable
disease, MS can have a significant impact on a person's ability to work. Understanding disclosure, workplace accommodations
and available resources will help you navigate your career decisions while
living with MS.
Join Steve Nissen, Senior
Director of Employment and Community Programs at the National Capital
Chapter, National MS Society, to discuss employment issues for people
with multiple sclerosis.
TUESDAY, July 17, 2012 (MedPage Today) — The interferon beta drugs widely used in relapsing-remitting multiple sclerosis (MS) may not delay progression of the disease in real-world practice, researchers found.
In a prospective registry, the drugs didn't predict a lower risk of becoming disabled compared with untreated contemporary controls, instead yielding a hazard ratio of 1.30 after adjustment for disease duration and other baseline factors.
The numbers looked a little better for interferon beta users when compared with untreated historical controls from the pre-interferon era, but they still didn't reach significance, Helen Tremlett, PhD, of the University of British Columbia in Vancouver, and colleagues reported in the July 18 issue of the Journal of the American Medical Association.
"The study is useful in terms of giving patients realistic expectations on what they can hope to gain in terms of benefits from the drug treatments," Tremlett said in a video interview with the journal.
However, clinicians and patients shouldn't abandon interferon beta over these results, Tobias Derfuss, MD, and Ludwig Kappos, MD, both of the University Hospital Basel, Switzerland, cautioned in an accompanying editorial.
Controlled clinical trials have shown that interferon beta and other disease-modifying drugs cut down on relapse frequency and related progression of impairment and disability in MS.
"The common but disputed assumption has been that these clinical and radiographic findings in studies limited to 2 to 3 years' duration translate into long-term benefits, with delay or prevention of long-term disability in patients typically seen in a neurological practice," the editorial explained, which is key for a disease with an average duration of 30-plus years.
But drug efficacy often isn't as good in real-world settings with broader patient populations and much longer durations of treatment without the highly structured, supportive follow-up used in trials, Tremlett's group noted.
The bottom line is that the results call into question the assumption of long-term benefit, which remains unproven, the researchers and editorialists agreed.
LUND, SWEDEN, Jul 17, 2012 -- Active Biotech today announced that the European Medicines Agency (EMA) has completed the validation process for the marketing authorization application (MAA) of the medicinal product laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
The completion of the MAA validation process and acceptance for review now leads to the formal scientific review process by EMA's Committee for Medicinal Products for Human Use.
This acceptance of the EMA filing for review triggers a milestone payment of USD 5 million to Active Biotech from Teva.
The MAA submission is supported by a pooled analysis of data from the two global Phase III clinical trials in RRMS involving more than 2,400 patients treated for two years, the ALLEGRO and BRAVO trials. This analysis further strengthens the positive results achieved in the studies.
Additionally, Active Biotech and Teva continue to work with the Food and Drug Administration to determine the regulatory path forward for laquinimod in the U.S.
Laquinimod is an oral, once-daily CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of MS. In animal models laquinimod crosses the blood brain barrier to potentially have a direct effect on resident CNS inflammation and neurodegeneration. The global Phase III clinical development program evaluating oral laquinimod in MS includes two pivotal studies, ALLEGRO and BRAVO.
In addition to the MS clinical studies, laquinimod is currently in Phase II of development for Crohn's disease and Lupus.
A buildup of sodium in the brain detected by magnetic resonance imaging (MRI) may be a biomarker for the degeneration of nerve cells that occurs in patients with multiple sclerosis (MS), according to a new study published online in the journal Radiology.
The study found that patients with early-stage MS showed sodium accumulation in specific brain regions, while patients with more advanced disease showed sodium accumulation throughout the whole brain. Sodium buildup in motor areas of the brain correlated directly to the degree of disability seen in the advanced-stage patients.
"A major challenge with multiple sclerosis is providing patients with a prognosis of disease progression," said Patrick Cozzone, Ph.D., director emeritus of the Center for Magnetic Resonance in Biology and Medicine, a joint unit of National Center for Scientific Research (CNRS) and Aix-Marseille University in Marseille, France. "It's very hard to predict the course of the disease."
In MS, the body's immune system attacks the protective sheath (called myelin) that covers nerve cells, or neurons, in the brain and spinal cord. The scarring affects the neurons' ability to conduct signals, causing neurological and physical disability. The type and severity of MS symptoms, as well as the progression of the disease, vary from one patient to another.
Dr. Cozzone, along with Wafaa Zaaraoui, Ph.D., research officer at CNRS, Jean-Philippe Ranjeva, Ph.D., professor in neuroscience at Aix-Marseille University and a European team of interdisciplinary researchers used 3 Tesla (3T) sodium MRI to study relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease in which clearly defined attacks of worsening neurologic function are followed by periods of recovery. Sodium MRI produces images and information on the sodium content of cells in the body.
"We collaborated for two years with chemists and physicists to develop techniques to perform 3T sodium MRI on patients," Dr. Zaaraoui said. "To better understand this disease, we need to probe new molecules. The time has come for probing brain sodium concentrations.
Using specially developed hardware and software, the researchers conducted sodium MRI on 26 MS patients, including 14 with early-stage RRMS (less than five years in duration) and 12 with advanced disease (longer than five years), and 15 age- and sex-matched control participants. In the early-stage RRMS patients, sodium MRI revealed abnormally high concentrations of sodium in specific brain regions, including the brainstem, cerebellum and temporal pole. In the advanced-stage RRMS patients, abnormally high sodium accumulation was widespread throughout the whole brain, including normal appearing brain tissue.
The message shown below was just sent to me from a friend and has nothing to do with MS. Read it and share it as it really does make a good point
Why do I have a variety of
friends & family, who are all so different in character? How can I get
along with them all? I think that each one helps to bring out a
"different" part of me. With one of them I am polite. With another I
joke. I sit down and talk about serious matters with one. With another I laugh
a lot. I listen to one persons problems. Then I listen to another one's
advice for me. Those around me are like pieces of a
jigsaw puzzle. When completed, they form a treasure box. A treasure of peoples
souls! They understand me better than I understand myself. They support me
through good days and bad. Real Age doctors tell us that these people are good for
our health. Dr. Oz calls them Vitamin F (for Friends & family) and counts
their benefits as essential to our well being. Research shows that people
in strong social circles have less risk of depression and terminal strokes. If
you enjoy Vitamin F constantly you can be up to 30 years younger than your real
age. The warmth of their contact stops stress and does so even in your
most intense moments. It decreases the chance of a cardiac arrest or stroke by
50%. I'm so happy that I have a stock of Vitamin F! In summary, we should value our "F"'s and keep in
touch with them. We should try to see the funny side of things and laugh
together and pray for each other in tough moments. Some of my F's are on
line. I know that I'm part of their circle because their names appear
on my computer screen, and I feel blessed that they care as much for me as I
care for them, and that they're a part of my circle of F people.
I want to thank my friend for sending this to me. Thanks Jay... Regards, Stuart